As a result of intensive research to find a drug with an effect similar to that of sodium cromoglycate (SCG) in the prophylaxis of asthma but with oral administration, ketotifen has recently been introduced. We report on two trials to assess its efficacy in patients with bronchial asthma. Trial 1, a double-blind, double-dummy comparison between ketotifen, 1 mg b.i.d., and SCG, 20 mg q.i.d. in atopic adult asthmatics not requiring oral corticosteroids and taking only minimal anti-asthmatic treatment is in progress. Symptomatic assessment is made by questionnaire and objective assessment by twice daily PEFR measurements and records of concurrent drug use.
investigating the steroid-sparing effect of inhaled steroid aerosols where a difference of 3.0 mg between active and placebo aerosol was noted. The main side-effect of ketotifen was drowsiness, occurring in less than 10% of the patients and not necessitating taking any of them off the drug. The final place of ketotifen in the overall management of asthma remains to be determined but the steroid-sparing effect demonstrated in the second trial clearly indicated that the drug deserves further careful evaluation in a clinical setting. Reference 1 British Thoracic and Tuberculosis Association: A controlled trial of inhaled corticosteroids in patients receiving Prednisone tablets for asthma. Br. J. Dis. Chest 70: 95 (1976) .
